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Summary Serum levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-2 (TIMP-2) were evaluated as
prognostic indicators of the recurrence of urothelial cancer. Sera were obtained from 127 healthy control subjects and 97 urothelial cancer
patients who underwent complete resection and were measured for MMP-2 and TIMP-2 using a one-step enzyme immunoassay. The
relationship between the serum MMP-2/TIMP-2 ratio and the recurrence of urothelial cancer was examined. The mean serum MMP-2/TIMP-2
ratio in the 31 advanced urothelial cancer patients with recurrence was significantly higher than that in the 22 patients without recurrence
(P = 0.0029) and in the 44 superficial bladder cancer patients (P < 0.0001). The 1- and 3-year disease-free survival rates in the patients
with high MMP-2/TIMP-2 ratios (50% and 12%) were significantly poorer than those of the patients with normal ratios (82% and 56%)
(P=0.0152). Univariate and multivariate analyses of recurrence demonstrated that the serum MMP-2/TIMP-2 ratio is a significant
independent indicator of advanced urothelial cancer. Our results indicate that an imbalance between the serum levels of MMP-2 and TIMP-2
could be a new predictor of recurrence in advanced urothelial cancer patients.
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Matrix metalloproteinases (MMPs) has been shown to play a role
in the degradation of the vascular basement membrane, whose
major component is type IV collagen (Liotta et al, 1991; Nakajima
et al, 1991). Matrix metalloproteinase-2 (MMP-2, gelatinase A, a
72-kDa type IV collagenase) is produced by both malignant cells
and stromal cells such as fibroblasts, macrophages and vascular
endothelial cells (Nakajima et al, 1991). Many investigators have
demonstrated that human and rodent metastatic malignant cells
produce larger amounts of MMP-2 than do non-metastatic cells,
both in vitro and in vivo (Liotta et al, 1980; 1991). Tissue inhibitor
of metalloproteinases-2 (TIMP-2), an unglycosylated protein of
21-kDa molecular weight, strongly inhibits the biological activity
of MMP-2, and was shown to strongly inhibit cancer invasion,
metastasis, growth and angiogenesis in some rodent and human
tumours (Stetler-Stevenson et al, 1989; DeClerck et al, 1992).
Therefore, it is likely that an imbalance in the MMP-2 and TIMP-
2 ratio plays an important role in cancer invasion, metastasis and
angiogenesis (Liotta et al, 1991; DeClerck et al, 1994). Some
investigators have revealed a relationship between the recurrence
and the expression of MMP-2 and TIMP-2 in bladder cancer
tissues (Davies et al, 1993; Grignon et al, 1996). However, there
are no previous reports concerning the relationship between the
serum MMP-2/TIMP-2 ratio and the recurrence ofhuman urothe-
lial cancer. In this study, the serum levels of MMP-2 and TIMP-2
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were determined in human urothelial cancer patients, and the rela-
tionship between the serum MMP-2/TIMP-2 ratio and invasion
and metastasis in urothelial cancer was examined. We discuss the
diagnostic value of an imbalance in the serum MMP-2/TIMP-2
ratio for the recurrence of advanced urothelial cancer after
complete resection.
PATIENTS AND METHODS
Between January 1986 and October 1994, sera were obtained from
97 patients [44 with superficial bladder cancer(<pTI) and 53 with
advanced urothelial cancer with muscular invasion (2 pT2) or
metastasis] before they underwent complete resection. Informed
consent was obtained from all patients for measuring serum
MMP-2 and TIMP-2. The study was carried out with ethical
approval. The sera were stored at -80°C until use. The patholog-
ical stages were determined according to the TNM classification
of urothelial cancer. The histology and differentiation of the
tumours were determined according to the World Health
Organization (WHO) classifications. Normal serum MMP-2 and
TIMP-2 levels were determined from healthy control subjects (85
males and 42 females; 18-69 years old, median 59 years). The
maximum diameter ofeach bladder tumour was determined endo-
scopically. The clinicopathological features of the patients are
shown in Table 1.
The concentration of serum MMP-2 was measured by a one-
step sandwich enzyme immunoassay (EIA) system using murine
monoclonal antibodies raised against the purified proMMP-2 and
an oligopeptide from residue 17 to 35 ofthe amino terminal region
on the human MMP-2 sequence, as previously described
(Fujimoto et al, 1993a). The sensitivity of this EIA system was
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Table 1 Clinicopathological features of urothelial cancer patients who underwent complete resection
Variables Number of patients (n = 97)
Superficial Bcas (n = 44) Advanced Bcab (n = 29) Upper urothelialc (n = 24)
Sex
Male/female 32/12 25/4 18/6
Age (years)
Median (range) 64 (31-94) 66 (40-87) 66 (54-81)
Histology
TCCd
Gl 19 1 1
G2 19 9 11
G3 6 15 12
SCC ADEe 0 4 0
PTstage
Ta 12 0 0
Ti 32 2' 3'
T2 0 12 11
T3a 0 3 0
T3b 0 12 8
T4 0 0 2
Lymphnode metastasis
Negative 44 22 17
Positive 0 7 7
Lymphvascular involvement
Negative 28 12 11
Positive 2 17 13
Unknown 14 0 0
Maximal tumour size in diameter (cm)
<1 8 0 NDg
1-3 10 7
23 2 6
Unknown 24 16
aSuperficial bladder cancer; badvanced (muscular invasive or metastatic) bladder cancer; cadvanced upper urothelial cancer;
dtransitional cell carcinoma; esquamous cell carcinoma and adenocarcinoma; 'all patients with PT1 disease had lymph node
metastasis; snot detected.
2.4 pg per assay (0.24 ng ml-'), and linearity was obtained
between 10 and 5000 pg per assay (1.0-500 ng ml-'). The concen-
tration of serum TIMP-2 was similarly determined using a murine
monoclonal antibody against human TIMP-2, as previously
described (Fujimoto et al, 1993b). The sensitivity ofthis EIA was
16 pg per assay (1.6 ng ml-'), and linearity was obtained between
63 and 500 pg per assay (6.3-50 ng ml-'). As the monoclonal anti-
body used in the present study was raised against the N-terminal
domain peptide of proMMP-2, it recognizes free proMMP-2 but
does not detect inactivated MMP-2 bound to TIMP-2. There is no
free active form of MMP-2 in the serum. When the sera were
analysed by the combination of zymography and affinity chro-
matography with anti-TIMP-1 and anti-TIMP-2 monoclonal anti-
bodies, the amounts of the active form of MMP-2 in sera were
found to be extremely low and completely bound to TIMPs (data
not shown). Thus, we measured only proMMP-2 level in the
serum.
All superficial bladder cancers were resected endoscopically,
and the patients were observed for recurrence over a median
period of 30 months (10-67 months). Ofthe 29 advanced bladder
cancer patients, 26 underwent radical cystectomy and pelvic
lymph node dissection, and three underwent partial cystectomy
and hemipelvic lymph node dissection; the median observation of
these 29 patients was 28 months (4-98 months). All 24 upper
urothelial cancer patients received nephroureterectomy, partial
cystectomy and regional lymph node dissection; the median
observation was 20 months (3-107 months).
Thepost-operative examinations forrecurrence were carried out
by pelvic and abdominal computerized tomography (CT), chest
radiograph and routine blood tests at 3-month intervals for 3 years
afterthe surgery, andbone scans wereperformed at 6-month inter-
vals forthe sameperiod. These examinations were then carried out
at 6-month intervals until 5 years after the surgery. After 5 years,
the examinations were performed annually. When the patients had
any neurological symptoms, such as headache or vomiting, they
were examined by a brain CT scan. Only visceral, skeletal and
lymph node metastases were regarded as recurrence for the
purpose ofthis study.
The differences in the serum levels of MMP-2 and TIMP-2
among the superficial bladder cancerpatients, the healthy controls
and the advanced urothelial cancer patients were examined using
the Mann-Whitney U-test. The significance of the elevations in
the serum levels of MMP-2, TIMP-2 and the serum MMP-
2/TIMP-2 ratio was categorized into groups and then aX2-test was
carried out. The disease-free survival rate was calculated
according to the method ofKaplan-Meier and compared using the
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Table 2 Serum levels of MMP-2, TIMP-2 in healthy controls and urothelial cancer patients
Variables n Mean ± s.d. (ng ml-1) Elevation (%)a
MMP-2 PLvalueb TIMP-2 PLvalueb MMP-2 P.valuec TIMP-2 P.valuec
Healthy controls 127 549 ± 90.5 0.820 60.3 ± 19.8 0.40 5 (4) 1.00 8 (6) 0.065
Superficial Bcad 44 550 ± 142 - 57.3 ± 19.8 - 2 (4) - 7 (16) -
Advanced Uro Cae 53 702 176 <0.0001 77.5±31.0 0.0002 22 (41) <0.0001 11 (21) 0.607
Without recurrence 22 647 150 0.010 10060' 89-9+40.8 <0.0001 0011, 7(32) 0.004810.268' 9 (41) 0.035 0.0044'
With recurrence 31 739 185 <0.0001 J 68.4 ± 16.7 0.013 1001 15 (48) <0.0001 J 2 (6) 0.292
aSerum levels of MMP-2.730 ng ml-'; serum levels of TIMP-2 2 94 ng ml-1, bMann-Whitney U-test. Healthy controls and advanced urothelial cancer were
compared against superficial bladder cancer; cX2-test; 'Mann-Whitney U-test; advanced urothelial cancer without recurrence vs advanced urothelial cancer with
recurrence. dsuperficial bladder cancer; eadvanced (muscular invasive or metastatic) urothelial cancer
log-rank test. Disease-free survival was defined as the time from
the surgery to the detection of the first local recurrence or distant
metastasis, or to the end ofthe study. Factors related to recurrence
in the patients who underwent complete resection were analysed
by Cox's proportional hazard regression model (Cox, 1972).
P-values < 0.05 were regarded as significant.
RESULTS
Serum levels of MMP-2 and TIMP-2
The serum levels of MMP-2 and TIMP-2 obtained in this study
are summarized in Table 2. The serum levels of these enzymes
and inhibitors were not related to sex or age in the healthy control
subjects (data not shown). The mean +2 s.d. levels of serum
MMP-2 and TIMP-2 in the healthy controls were 730 ng ml' and
94 ng ml-' respectively; any higher values were regarded as
'elevated'. There was no significant difference in these values
between the healthy control subjects and the superficial bladder
cancer patients. In contrast, the serum MMP-2 and TIMP-2 levels
in the advanced urothelial cancer patients (702 ± 176 and
77.5 ± 31.0 ng ml' respectively) were significantly higher than
those in the superficial bladder cancer patients (P < 0.0001 and
P = 0.0002 respectively). The elevation of serum MMP-2 in the
advanced urothelial cancer patients was also significantly higher
than that in the superficial bladder cancer patients (P < 0.0001).
However, the elevation of serum TIMP-2 in the advanced urothe-
lial cancer patients was not significantly different compared with
that in the superficial bladder cancer patients. Moreover, there
was no significant difference between the levels in the advanced
bladder and upper urothelial cancer patients (data not shown).
There was also no correlation between the serum levels ofMMP-2
or TIMP-2 and tumour size (data not shown). Ofthe 53 advanced
urothelial cancer patients, 31 had recurrence and the remaining 22
had no recurrence after the surgery. The serum levels of MMP-2
in the 31 patients with recurrence (739 ± 185 ng ml-') were
significantly higher than those in the 44 superficial bladder
cancer patients (550 ± 142 ng ml-') (P < 0.0001), but the value
was not significantly different from those in the 22 advanced
urothelial cancer patients without recurrence (647 ± 150 ng ml-')
(P = 0.060). Moreover, the serum levels of TIMP-2 in the 22
patients without recurrence (89.9 ± 40.8 ng ml-') were signifi-
cantly higher than those in the 44 superficial bladder cancer
patients (57.3 ± 19.8 ng ml-') (P < 0.0001) and those in the 31
patients with recurrence (68.4 ± 16.7 ng ml-') (P = 0.011).
The serum MMP-2/TIMP-2 ratios
The mean+2 s.d. of the serum MMP-2/TIMP-2 ratio in the
healthy control subjects was 11.0; any higher value was regarded
as elevated. The serum MMP-2/TIMP-2 ratios were not related to
tumour differentiation or pT stage (data not shown). A significant
difference was found only between patients with positive lymph
node metastasis (12.2 ± 3.16) and those who were negative (9.72
± 4.02) (P = 0.04). The elevation of the serum MMP-2/TIMP-2
ratio in the advanced urothelial cancer patients with recurrence
(15 out of 31, 48.4%) was significantly higher than that in the
advanced urothelial cancer patients without recurrence (4 out of
22, 18.2%)(P = 0.0408) and the superficial bladder cancer group
(3 out of44, 6.8%)(P < 0.0001). It is noted that the mean ratio in
the 31 advanced urothelial cancer patients with recurrence
(11.2 ± 3.43, range 4.23-21.06) was significantly higher than
that in the 22 without recurrence (8.48 +4.13, range 2.66-20.0)
and than that in the 44 superficial bladder cancer patients
(7.76 ± 1.55, range 3.52-13.3) (P = 0.0029 and P < 0.0001 respec-
tively) (Figure 1).
Disease-free survival in advanced urothelial cancer
patients according to serum MMP-2, TIMP-2 levels and
MMP-2/TIMP-2 ratios
There was no significant difference in disease-free survival
between the patients with elevated serum levels of MMP-2 and
those with normal levels of the enzyme (Figure 2A). The serum
level of TIMP-2 itself was also not correlated with disease-free
survival (Figure 2B). Among the patients with advanced urothelial
cancer, 19 patients had high MMP-2/TIMP-2 ratios (2 11.0) and
34 showed normal ratios (< 11.0). The 1- and 3-year disease-free
survival rates of the patients with high MMP-2/TIMP-2 ratios
were 50% and 12%, respectively, significantly unfavourable
compared with those with a low ratio (82% and 56% respectively)
(P = 0.0152) (Figure 2C).
Univariate and multivariate analyses for recurrence in
advanced urothelial cancer patients who underwent
complete resection
The univariate analysis determined that significant predictors of
recurrence were the serum MMP-2/TIMP-2 ratio (P = 0.0228),
pT stage (P = 0.0056) and lymph node metastasis (P = 0.0448)
(Table 3). The serum MMP-2/TIMP-2 ratio (P = 0.0249), pT stage
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Figure 1 The serum MMP-2/TIMP-2 ratios in the 44 superficial bladder
cancer and 53 advanced urothelial cancer patients. The mean serum MMP-
2/TIMP-2 ratios in the advanced urothelial cancer patients with recurrence
was significantly higher than that in the advanced urothelial cancer patients
without recurrence and in the superficial bladder cancer patients (P= 0.0029
and (P < 0.0001, Mann-Whitney U-test). Data are means ± standard
deviation
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(P = 0.00 1), and lymph node metastasis (P = 0.0260) were also
defined as significant independent predictors of recurrence using
multivariate analysis.
DISCUSSION
MMP-2 is one of the important proteases that degrades vascular
basement membranes and extracellular matrices in the multiple
metastatic process (Liotta et al, 1991; Nakajima et al, 1991;
DeClerck et al, 1994). This enzyme also enhances the infiltration
and migration of vascular endothelial cells, and thus induces
neovascularization in malignant tumours (Liotta et al, 1991;
Nakajima et al, 1991; DeClerck et al, 1994). The levels of MMP-2
and MMP-9 in high-grade or invasive bladder cancers were found to
be significantly higher than those in low-grade and non-invasive
bladder cancers, indicating that MMP-2 and MMP-9 may play a role
in the invasion and metastasis ofbladder cancer (Davies et al, 1993).
TIMPs are known for their anti-neoplastic activity (Albini et al,
1991; Montgomery et al, 1994). The transfection of sense TIMP- I
complementary DNA into metastatic cells decreased their inva-
sive, tumorigenic and metastatic capacities (DeClerck et al, 1992;
Khokha et al, 1994). Moreover, TIMPs are reported to inhibit
angiogenesis, probably by affecting endothelial cell invasion,
migration and proliferation (Moses et al, 1990; Takigawa et al,
1990; Liotta et al, 1991; DeClerck et al, 1994). The high level of
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Figure 2 Disease-free survival of the 53 advanced urothelial cancer
patients after complete resection according to the serum levels of MMP-2
(A), TIMP-2 (B) and MMP-2/TIMP-2 ratios (C). The 1- and 3-year disease-
free survival rates of the patients with high MMP-2/TIMP-2 ratios (> 11.0)
were significantly unfavourable compared with the patients with lower ratios
(< 11.0)(P= 0.0152; log-rank test)
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Table 3 Prognostic factors of recurrence (univariate and multivariate analyses)
Disease-free survival
Univariate Multivariate
Hazard ratio (95% CI) P-value Hazard ratio (95% Cl) P-value
MMP-2/TIMP-2 (<11.0 vs 2 11.0) 2.31 (1.12-4.74) 0.0228 2.39 (1.12-5.10) 0.0249
Age (<61 years vs .61 years) 1.14 (0.54-2.43) 0.734 2.18 (0.91-5.22) 0.0815
Sex (Male vs female) 0.91 (0.37-2.22) 0.835 0.998 (0.37-2.68) 0.999
Grade (Gl vs G2 vs G3) 0.93 (0.46-1.85) 0.826 0.73 (0.32-1.65) 0.446
Stage (Ti vs T2 vs T3 vs T4) 1.95 (1.22-3.14) 0.0056 2.94 (1.54-5.61) 0.0011
Lymphovascular involvement 1.58 (0.75-3.31) 0.231 0.74 (0.28-2.01) 0.5622
(negative vs positive)
Lymph node metastasis 2.15 (0.99-4.69) 0.0448 2.78 (1.13-6.84) 0.0260
(negative vs positive)
Cl, confidence intervals.
TIMP-2 expression as detected by immunohistochemistry was
associated with poor outcome in invasive bladder cancer patients
(Grignon et al, 1996). However, several investigators have shown
that the balance between MMPs and their inhibitors (TIMPs)
modulated endothelial cell morphogenesis in vitro, and that TIMPs
inhibited the early events in tube formation by endothelial cells on
Matrigel (Schnaper et al, 1993). Therefore, MMPs and TIMPs in
circulating body fluids may also contribute to the regulation of
tumour metastasis, invasion and angiogesesis (Liotta et al, 1991;
DeClerck et al, 1994).
The purpose of the present study was to determine whether the
serum MMP-2/TIMP-2 ratio could be a predictor of invasion,
metastasis and recurrence in advanced urothelial cancer patients
who have undergone complete resection. Our results demonstrated
that the serum levels of MMP-2 and TIMP-2 in the advanced
urothelial cancer patients were significantly higher than those in
the superficial bladder cancerpatients. Moreover, the serum MMP-
2/TIMP-2 ratio in the advanced urothelial cancer patients with
recurrence was significantly higher than those in the superficial
bladder cancer and advanced urothelial cancer patients without
recurrence. In fact, the median disease-free survival ofthe patients
with higher values of MMP-2/TIMP-2 (211.0) was significantly
shorter than that of the patients with normal values (<11.0).
However, the disease-free survival was not correlated with the low
level of serum MMP-2. In addition, although the results shown in
Figure 2B suggest a possible correlation between the serum TIMP-
2 level and the disease-free survival, high levels of serum TIMP-2
alone were not significantly correlated with the disease-free
survival. Nevertheless, the imbalance of these enzymes and
inhibitors is most likely an important factor in urothelial cancer
invasion and metastasis, and, thereby, recurrence. There have been
several studies on the inhibition oftumour invasion and metastasis
by TIMP-1 (Schultz et al, 1988; Alvarez et al, 1990) and TIMP-2
(Albini et al, 1991; DeClerck et al, 1991). Koop et al (1994) found
that the decreased metastatic ability of TIMP-overexpressing
B16F10 melanoma cells was due to the effects ofTIMP on tumour
growth after tumour cell extravasation in the metastatic target
organ. TIMP-2 has been shown to inhibit the basic fibroblast
growth factor stimulation ofendothelial cell growth (Murphy et al,
1993). In addition, synthetic MMP inhibitors have been demon-
strated to suppress primary tumour growth (Naito et al, 1994;
Wang et al, 1994). Therefore, MMP inhibitors could be inhibitory
against not only tumour invasion but also tumour growth, through
the inactivation ofcell-associated MMPs.
In the present study, we noted that when the serum MMP-
2/TIMP-2 ratio had been within the normal range (< 11.0), the
secondary tumour at any metastatic site did not grow well.
Therefore, even ifmicrometastatic lesions were formed before the
operation, high levels of serum TIMP-2 would prevent metastatic
tumour cells from developing further visible colonies.
Using multivariate analysis of recurrence we found that the
serum MMP-2/FIMP-2 ratio is a new independent predictor
comparable with traditional prognostic factors such as pT stage
and lymph node metastatic status (Skinner et al, 1991).
In conclusion, our results indicate that the imbalance of serum
MMP-2 and TIMP-2 (the MMP-2/TIMP-2 ratio) could be a new
predictor of recurrence and may help us to determine whether or
not patients with advanced urothelial cancer need intensive
therapy, such as adjuvant chemotherapy, after complete resection.
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